Samsung Ventures has invested in BrickBio, a biotechnology firm situated in Boston, Massachusetts that is focused on creating precision biologics by utilizing an extended genetic code.
The sum invested by Samsung Ventures-managed Samsung Life Science Fund, which was established in conjunction with Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), was not made public.
The money will be used by the business to enhance and further develop its preclinical assets and protein engineering technologies.
BrickBio, a biotechnology company led by CEO John Boyce, offers a site-specific and site-selective platform that spans both prokaryotic and eukaryotic expression systems.
This platform enables the development of novel biologics and protein therapeutics with improved properties, such as increased half-life, dosage, and efficacy. It can optimize any conjugate using a set of bioconjugation handles.
The business is growing its therapeutic initiatives, which include innovative scaffolds, bispecific conjugates, and ADCs.
About BrickBio, Inc.
With its site-specific and site-selective platform, Boston-based biotechnology business BrickBio Inc. enables next-generation unnatural amino acid linked protein conjugation. Prokaryotic and eukaryotic expression systems are covered by the platform technology, which makes it possible to create novel biologics and protein therapies with improved half-lives, dosages, and efficacies. With the widest range of bioconjugation tools at its disposal, BrickBio is able to optimize any conjugate and is in a unique position to advance the field of biologics by selectively altering several different locations on a single protein. BrickBio is growing its range of medicinal projects to include innovative scaffolds, bispecific conjugates, and ADCs.
